RxDoctor Payments Data

Sejal Patel, MD

Ophthalmology · New York, NYNPI 1770946949

Payments from drug & device makers

$1,543in general payments, 2019–2025

Across 31 payments — averaging $49.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$465
  • Nova Eye, Inc.$225
  • Galderma Laboratories, L.p.$184
  • Alcon$167
  • Biotissue Holdings Inc.$125
  • Tarsus Pharmaceuticals, Inc.$110
  • plus $268 from 5 others

What the payments were for

  • Food & beverage$1,543100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,543 in reported general payments places this provider in the 50th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$464,566
Medicare patients
1,228
Services billed
3,870

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine132$152,425
XdemvyLotilaner47$86,968
LumiganBimatoprost147$84,251
XiidraLifitegrast47$82,642
MieboPerfluorohexyloctane/Pf38$43,072
Cyclosporine71$42,843
RocklatanNetarsudil Mesylat/Latanoprost68$35,922
RhopressaNetarsudil Mesylate35$20,211
CombiganBrimonidine Tartrate/Timolol26$13,251
TyrvayaVarenicline Tartrate14$13,036
ProlensaBromfenac Sodium35$11,996
SimbrinzaBrinzolamide/Brimonidine Tart34$11,279
VyzultaLatanoprostene Bunod19$9,988
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol51$9,636
Bromfenac Sodium26$7,365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$49$255,049320 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$74$135,702104 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$110$86,96847 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$100$56,133103 claims
Oyster Point Pharma, Inc.Tyrvaya$13$13,03614 claims
AlconSimbrinza$167$11,27934 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →